
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health is a leading company in the integrated population health management industry, with a strong focus on delivering high-quality, cost-effective medical care through their Care Partners segment. The company's use of AI technology and acquisition of Prospect Medical are expected to contribute to revenue growth and risk-based contracts, but they face competition and uncertainties in Medicare payments. Despite these challenges, Astrana Health remains on track to achieve their goals, with slightly above and below average scores for Medicare fee-for-service and Medicare Advantage, and potential risks related to value-based care, contract renewals, healthcare utilization, and accounting issues.
Bears say
Astrana Health is facing several market-level and company-specific risks that could hinder its growth potential. These include intense competition from larger value-based health management companies in the Medicare Advantage space, pressure from smaller and recent entrants, the financial health of its payer partners, and potential changes made by CMS to MA regarding payments. Moreover, Astrana's reliance on the Medicare market and potential declines in membership could also negatively impact the company's revenue and profitability. Additionally, the company's high debt load may limit its ability to invest in new opportunities and expand the business. Despite its strong track-record in delivering high-quality care and generating cost-savings, these risks could impact Astrana's growth and make it a less compelling option for physicians and payers.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares